Fate Therapeutics Inc

Fate Therapeutics is a biopharmaceutical company. The company's off-the-shelf, induced pluripotent stem cells (iPSC)-derived cellular immunotherapy pipeline include: FT500, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy for the treatment of solid tumors; and FT516, which is an off-the-shelf NK cell cancer immunotherapy. The company's other iPSC-derived cell product candidates include: FT301, an off-the-shelf, immuno-regulatory cell product candidate derived from a clonal master iPSC line. The company's allogeneic cellular immunotherapy pipeline include: ProTmune?, an investigational programmed cellular immunotherapy for use as an allogeneic hematopoietic cell transplantation cell graft.
  • TickerFATE
  • ISINUS31189P1021
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

ields Testing Support Ahead Of FOMC Meeting We continue to see signs of improving risk appetites alongside healthy market dynamics. As a result, our outlook remains constructive. A breakout to new highs in the Russell 2000 (IWM) and Russell Micro-Caps (IWC), above $234.50 and $159, would likely cause us to shift to an outright bullish stance. Small- & Micro-Caps. The Russell 2000 (IWM) and Russell Micro-Caps (IWC) are testing key resistance at $234.50 and $159, respectively. Sustained breakouts above these levels would be a very healthy sign for the broad market and we would shift to an outr...

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

FATE THERAPEUTICS INCO. sees an upgrade to Slightly Negative thanks to a better star rating, but the title remains unattractive

The independent financial analyst theScreener just awarded an improved star rating to FATE THERAPEUTICS INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date June 8, 2021, the closing price was USD 79.23 and its target price was estimated at USD 49.60.

Wedbush Research

Wedbush Morning Call - Jun 07 2021 6:57AM

Fate Therapeutics Inc: 1 director sold

A director at Fate Therapeutics Inc sold 25,000 shares at 81.737USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names o...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

ields Testing Support Ahead Of FOMC Meeting We continue to see signs of improving risk appetites alongside healthy market dynamics. As a result, our outlook remains constructive. A breakout to new highs in the Russell 2000 (IWM) and Russell Micro-Caps (IWC), above $234.50 and $159, would likely cause us to shift to an outright bullish stance. Small- & Micro-Caps. The Russell 2000 (IWM) and Russell Micro-Caps (IWC) are testing key resistance at $234.50 and $159, respectively. Sustained breakouts above these levels would be a very healthy sign for the broad market and we would shift to an outr...

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 07 2021 6:57AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

FATE THERAPEUTICS INCO. sees an upgrade to Slightly Negative thanks to a better star rating, but the title remains unattractive

The independent financial analyst theScreener just awarded an improved star rating to FATE THERAPEUTICS INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date June 8, 2021, the closing price was USD 79.23 and its target price was estimated at USD 49.60.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch